In his weekly clinical update Dr. Griffin discusses detection of a highly divergent type 3 vaccine-derived poliovirus in a child with a severe primary immunodeficiency disorder, severe respiratory illnesses associated with rhinoviruses and/or enteroviruses including EV-D68, effects of vaccination and previous infection on Omicron infections in children, COVID-19-associated hospitalizations among vaccinated and unvaccinated adults 18 years or older in 13 US states, effectiveness of COVID-19 vaccines over time prior to Omicron emergence in Ontario, Canada, nasal IgA wanes 9 months after hospitalization with COVID-19 and is not induced by subsequent vaccination,  resistance of SARS-CoV-2 Omicron subvariant BA.4.6 to antibody neutralization, persistent circulating SARS-CoV-2 spike associated with post-acute COVID-19 sequelae, and impact of COVID-19 vaccination on the risk of developing long-covid and on existing long-covid symptoms.

Subscribe (free): Apple Podcasts, Google Podcasts, RSS, email

Become a patron of TWiV!

Links for this episode

• Detection of poliovirus in immunosuppressed child (CDC)
• Severe respiratory illnesses associated with rhinoviruses and/or enteroviruses (CDC)
• Effects of vaccination and previous Omicron infection in children (NEJM)
• COVID-19 hospitalizations among vaccinated and unvaccinated adults (JAMA)
• Effectiveness of vaccines prior to Omicron (IDSA)
• Nasal iga wanes 9 months after COVID hospitalization (medRxiv)
• Resistance of Omicron subvariant to antibody neutralization (BioRxiv)
• PAXLOVID patient eligibility screening checklist (FDA)
• Remdesivir fact sheet for providers (Veklury) 
• Bebtelovimab fact sheet for providers (FDA)
• SARS-CoV-2 spike is associated with post-acute sequelae (IDSA)
• Impact of vaccination on the risk of developing long-COVID (The Lancet)
• Contribute to Floating Doctors fundraiser at PWB
• Dr. Griffin's treatment guide (pdf)
• Letters read on TWiV 936
• Timestamps by Jolene. Thanks!

Intro music is by Ronald Jenkees Send your questions for Dr. Griffin to [email protected]